This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Letters to the Editor -
Two micron continuous wave laser vaporesection for the
treatment of benign prostatic hyperplasia
Wei-Jun Fu, Bao-Fa Hong, Yong Yang, Jiang-Ping Gao, Lei Zhang, Wei Cai, Yao-Fu Chen, Xiao-Xiong Wang
Department of Urology, Chinese People's Liberation Army General Hospital, Military Postgraduate Medical College,
Beijing 100853, China
Correspondence to: Dr Wei-Jun Fu, Department of Urology, Chinese People's Liberation Army General Hospital, Military Postgraduate
Medical College, Beijing 100853, China.
Tel: +86-10-6693-7107 Fax: +86-10-6818-5450 E-mail: fuweijun@hotmail.com
Received 2007-07-31 Accepted 2007-09-26
DOI: 10.1111/j.1745-7262.2008.00353.x
Dear Editor,
I'm Wei-Jun Fu, from Department of Urology, Chinese People's Liberation Army General Hospital, Military
Postgraduate Medical College, Beijing, China. We write to you to present an observation on the safety and clinical
effects of RevoLix 70 W 2 micron continuous wave laser vaporesection for the treatment of obstructive benign
prostatic hyperplasia (BPH). Because of the combination of the advantages of vaporization and resection, in our
experience, 2 micron wave laser vaporesection for treatment of BPH provides safe and effective relief from
obstructive BPH with minimal morbidity and rare bleeding.
A number of laser-based procedures have been developed to treat BPH. In the past the pulsed holmium laser has
been used for enucleation of the prostate, but the holmium laser is not the best form of energy when it comes to
cutting and vaporization of soft tissue [1]. More recently, photovaporization of the prostate using
potassium-titanyl-phosphate lasers has become more popular. But the lack of absorption in coagulated tissue impairs the vaporization
effect of the next tissue layer [2]. The continuous wave laser at 2 micron wavelength allows simultaneous
vaporization and resection of the prostate. Therefore, this technology is called "vaporesection of the prostate" and should
offer significant advantages over holmium laser and photovaporization.
We report our initial experience with the 2 micron continuous wave laser in treatment of the prostate for BPH. We
treated 56 patients with obstructive BPH between March 2006 and March
2007. The age of the patients ranged from 55 to 86 years, with a mean of 67 years. The mean prostate volume was
64.6 ± 12.2 mL, the preoperative total
prostate specific antigen (PSA) was 3.9 ± 1.4 ng/mL, and the mean
Qmax value was 5.2 ± 1.6
mL/s. In addition, the mean International Prostate Symptom Score (IPSS) and quality of life (QoL)questionnaire score was 23.8 ± 3.6
and 4.2 ± 0.2, respectively. The RevoLix 2 micron continuous wave laser (LISA Laser Products, Katlenburg, Germany)
was used at a power level of 70 W and in normal saline. A 550 micron RigiFib bare-ended fiber (RigiFib, LISA laser
products, Katlenburg, Germany) was used in combination with a 26 French continuous flow laser resectoscope. All
cases were followed up at average 6 months.
We found that the 2 micron laser provides immediate reduction of prostatic tissue and consistent transurethral
prostatectomy (TURP)-like capacity. Average resection time was (62.0 ± 14.6) min. Tissue samples are available for
histological analysis. No patient had intra-operative bleeding, and no blood transfusion was necessary. Foley
catheters were inserted immediately post operation and were removed on average 44.6 ± 21.6 h later. The IPSS and QoL
score decreased to 8.5 ± 2.3 and 1.9 ± 1.2, respectively. The
Qmax was 16.8 ± 2.3 mL/s
after treatment at average 6 months follow-up, which was significantly higher
than that before treatment (P < 0.05).
Apart from transient dysuria in two cases, all patients were
satisfied with voiding outcome, none had incontinence.
The 2 micron wavelength is delivered as a
continuous wave rather than pulsed, allowing for similar
vaporesection due to water absorption but without
damage or disturbance to adjacent tissue [3]. Another
important feature is that this laser wavelength allows the
use of clear safety glasses that do not produce any color
distortion and provide a clear view of the surgical site.
Therefore, the advantages of vaporesection are that it is
a safe, bloodless, efficient, and promising surgical
procedure for the treatment of BPH.
In our experience, patients have less blood loss and
shorter hospital stay in comparison to those underwent
electroresection. Follow-up data showed a significant
improvement in voiding symptoms and QoL. In many respects, 2 micron laser vaporesection is similar to TURP
procedure but without any of the side-effects. In fact, it
is expected that the 2 micron laser might challenge TURP
and could be a new gold standard for minimally invasive
treatment of BPH [4]. However, its drawbacks are the
longer operation time in comparison to electroresection
and the high acquisition costs of the laser. Our results
are short term and longer follow-up is needed before
RevoLix vaporesection can be considered a new gold
standard.
References
1 Montorsi F, Naspro R, Salonia A, Suardi N, Briganti A, Zanoni
M, et al. Holmium laser enucleation versus transurethral
resection of the prostate: results from a 2-center, prospective,
randomized trial in patients with obstructive benign prostatic
hyperplasia. J Urol 2004; 172: 1926_9.
2 Fu WJ, Hong BF, Wang XX, Yang Y, Cai W, Gao JP,
et al. Evaluation of greenlight photoselective vaporization of the
prostate for the treatment of high-risk patients with benign
prostatic hyperplasia. Asian J Androl 2006; 8: 367_71.
3 Teichmann HO, Herrmann TR, Bach T. Technical aspects of
lasers in urology. World J Urol 2007; 25: 221_5.
4 Bach T, Herrmann TR, Ganzer R, Burchardt M, Gross AJ.
RevoLix vaporesection of the prostate: initial results of 54
patients with a 1-year follow-up. World J Urol 2007; 25:
257_62.
|